Fig 2: TLN2 inhibits clear cell renal cell carcinoma (ccRCC) tumorigenesis partially by regulation of Wnt/ß catenin signaling. (A) TLN2 overexpression inhibited the expressions of Wnt/ß catenin-related genes. (B-D) Involvement of the Wnt/ß catenin pathway in the functions of TLN2 overexpression in ccRCC cell proliferation, invasion and migration (violet staining). *, P<0.05.

Fig 3: TLN2 overexpression inhibits cell cycle progression and promotes apoptosis of clear cell renal cell carcinoma (ccRCC) cells. (A,B) TLN2 overexpression inhibited ccRCC cell cycle progression. (C) TLN2 overexpression promoted apoptosis of ccRCC cells. (D) Western blotting detected the effects of TLN2 on apoptosis-related genes. *, P<0.05; **, P<0.01; ***, P<0.001.

Fig 4: TLN2 downregulated in clear cell renal cell carcinoma (ccRCC). (A) Expression patterns of TLN2 in ccRCC tumors (n=523) and normal tissues (n=100) from the GEPIA database. (B,C) TLN2 downregulated in ccRCC tissues at both the mRNA and protein level. (D) Expressions of TLN2 in ccRCC tissues detected by immunohistochemical staining. (E,F) TLN2 downregulated in ccRCC cells at both the mRNA and protein level. In the immunohistochemistry assay, the sections were stained with diaminobenzidine (DAB) and counterstained with hematoxylin. KIRC, Kidney Renal Clear Cell Carcinoma. *, P<0.05; **, P<0.01; ***, P<0.001.

Fig 5: Correlation of TLN2 expression in clear cell renal cell carcinoma (ccRCC) with survival rates of ccRCC patients. (A) Overall survival and (B) disease-free survival was better in the TLN2 high expression group than in the low expression group.